12.80

0.39% -0.05

After Hours: 12.80

Celcuity Inc (CELC)

Overview News Price History Option Chain Financials Discussions Forecast

Celcuity Inc stock is traded at $12.80, with a volume of 139.27K. It is down -0.39% in the last 24 hours and down -19.55% over the past month. Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Previous Close:

$12.85

Open:

$12.88

24h Volume:

139.27K

Relative Volume:

0.54

Market Cap:

$475.26M

Revenue:

Net Income/Loss:

$-63.78M

P/E Ratio:

-4.8302

EPS:

-2.65

Net Cash Flow:

$-53.91M

1W Performance:

-2.96%

1M Performance:

-19.55%

6M Performance:

-13.75%

1Y Performance:

-13.28%

1-Day Range:

$12.67

$13.02

1-Week Range:

$12.67

$14.19

52-Week Range:

$11.51

$22.19

Celcuity Inc Stock (CELC) Company Profile

Name

Celcuity Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

763-392-0767

Address

16305 36TH AVENUE N, MINNEAPOLIS, MN

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

CELC's Discussions on Twitter

Compare CELC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CELC Celcuity Inc	12.80	475.26M	0	-63.78M	-53.91M	-2.68
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Celcuity Inc Stock (CELC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-22-24	Initiated	Leerink Partners	Outperform
Feb-22-24	Initiated	Stifel	Buy
Dec-08-23	Initiated	H.C. Wainwright	Buy
Oct-08-21	Initiated	Canaccord Genuity	Buy
Sep-07-21	Initiated	Jefferies	Buy
Jul-29-21	Initiated	Cowen	Outperform
Jul-27-21	Initiated	Needham	Buy
Jan-28-21	Reiterated	H.C. Wainwright	Buy
Dec-24-20	Reiterated	H.C. Wainwright	Buy
May-11-20	Resumed	Craig Hallum	Buy
Nov-20-18	Initiated	H.C. Wainwright	Buy

View All

Celcuity Inc Stock (CELC) Latest News

09:39 AM

Celcuity Inc. (NASDAQ:CELC) Shares Acquired by Braidwell LP - MarketBeat

09:39 AM

Nov 25, 2024

Celcuity Inc. (NASDAQ:CELC) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Nov 25, 2024

Nov 21, 2024

(CELC) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Nov 21, 2024

Nov 18, 2024

Celcuity’s (CELC) “Buy” Rating Reiterated at Needham & Company LLC - Defense World

Nov 18, 2024

Earnings call: Celcuity reports Q3 2024 financials and clinical trial updates - Investing.com

Nov 15, 2024

Celcuity's (CELC) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat

Nov 15, 2024

Celcuity Inc. (NASDAQ:CELC) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

RA Capital Management, L.P. Acquires New Stake in Celcuity Inc - GuruFocus.com

Nov 15, 2024